{"id":2202,"date":"2026-07-27T10:00:00","date_gmt":"2026-07-27T14:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2202"},"modified":"2026-07-27T20:04:28","modified_gmt":"2026-07-28T00:04:28","slug":"molecular-tumor-age-predicts-early-dlbcl-progression","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2202","title":{"rendered":"Molecular Tumor Age Predicts Early DLBCL Progression"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Ruijin Hospital (Shanghai Jiao Tong University School of Medicine)<\/p>\n

Event Type<\/strong><\/p>\n

Preclinical\/Translational Research Findings<\/p>\n

Modality<\/strong><\/p>\n

Transcriptomic biomarker (molecular-age score)<\/p>\n

Asset<\/strong><\/p>\n

Molecular-age risk score (research-stage biomarker, not a named clinical asset)<\/p>\n

Target<\/strong><\/p>\n

Age-associated, progression-linked transcriptional programs<\/p>\n

Disease Area<\/strong><\/p>\n

Diffuse large B-cell lymphoma (DLBCL), early progression (POD24) risk<\/p>\n

Summary<\/h4>\n

A same-day Leukemia study developed a transcriptome-derived molecular-age score for diffuse large B-cell lymphoma and linked age acceleration to progression within 24 months after R-CHOP. Across discovery and external cohorts, molecular age was more strongly associated with progression-free survival than chronological age, with concordance-index improvements of 0.08\u20130.14. The work reframes aging as a tumor-intrinsic and microenvironmental state rather than a demographic variable, but the score is retrospective, cohort-trained, and not validated as a treatment-selection test.<\/p>\n

Investigators derived molecular-age scores from age-associated, progression-linked transcriptional programs in independent DLBCL cohorts.<\/p>\n

Higher molecular age correlated with inferior progression-free survival and identified greater overall and 24-month progression risk than chronological age \u226560.<\/p>\n

The reported concordance index improved by 0.08\u20130.14 over chronological age across cohorts.<\/p>\n

Accelerated tumors showed B-cell-intrinsic and extracellular\/microenvironmental dysregulation. Code and multiple source datasets were made available.<\/p>\n

Biological interpretation<\/h4>\n

The score may capture stress, inflammatory, immune, and stromal programs that accumulate independently of calendar age and influence treatment resistance.<\/p>\n

Because progression-associated genes contributed to score construction, some prognostic performance may reflect outcome-informed feature selection rather than independent aging biology.<\/p>\n

Alternative interpretations and validation gate<\/h4>\n

Interpretation A is that molecular age identifies biologically old tumors missed by standard clinical risk. Cross-cohort associations support this; retrospective derivation limits transportability.<\/p>\n

Interpretation B is that the model repackages known subtype and microenvironment risk. Overlap with established DLBCL biology supports this concern; incremental concordance suggests possible added information.<\/p>\n

Prospective locked-score validation, comparison with IPI and molecular subtype, assay reproducibility, and treatment-interaction testing would establish or falsify clinical utility.<\/p>\n

Translational implications<\/h4>\n

A reproducible assay could enrich trials for early-progression risk or identify age-related pathways for combination therapy.<\/p>\n

It should not currently determine treatment intensity because calibration, threshold stability, and clinical benefit from score-guided intervention are unknown.<\/p>\n

Evidence limitations<\/h4>\n

The publication is a retrospective letter using transcriptomic datasets with differing collection and treatment contexts.<\/p>\n

Association does not demonstrate that modifying an age-related program will improve outcome.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Same-day peer-reviewed Leukemia publication.<\/li>\n
  • Core lymphoma biomarker: transcriptomic molecular age and POD24 risk.<\/li>\n
  • Incremental prognostic association beyond chronological age.<\/li>\n
  • Open code supports independent replication.<\/li>\n
  • No prospective treatment-selection validation.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The study provides a useful biological framework and a potentially scalable risk feature, but not a ready clinical test.<\/p>\n

    Its value will depend on prospective incremental performance over IPI, cell-of-origin, genomic subtype, circulating tumor DNA, and early response.<\/p>\n

    Company and Product Background<\/h4>\n

    DLBCL is the most common aggressive B-cell lymphoma. Patients progressing within 24 months after first-line therapy have particularly poor subsequent outcomes.<\/p>\n

    Molecular-age models estimate age-related biological state from gene expression rather than date of birth.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 3\/5 \u2014 Medium-High. Importance:<\/strong> Moderate \u2014 the work introduces a cross-cohort lymphoma-risk framework with translational potential, though clinical utility is untested. Confidence:<\/strong> High on facts, Medium on interpretation \u2014 the analysis is peer-reviewed with multi-cohort data and available code, but retrospective, outcome-informed feature construction may overstate incremental value.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A same-day Leukemia study developed a transcriptome-derived molecular-age score for diffuse large B-cell lymphoma and linked age acceleration to progression within 24 months after R-CHOP. Across discovery and external cohorts, molecular age was more…<\/p>\n","protected":false},"author":1,"featured_media":2208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[182,206],"class_list":["post-2202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-diffuse-large-b-cell-lymphoma","tag-ruijin-hospital"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2202"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2202\/revisions"}],"predecessor-version":[{"id":2216,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2202\/revisions\/2216"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2208"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}